Kaitlyn Vann, DO
Family Medicine · Cleveland, GANPI 1417303199
Payments from drug & device makers
Across 154 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$395
- Novo Nordisk$287
- AstraZeneca$271
- Amgen$228
- Pfizer$162
- Dexcom, Inc.$151
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,65499%
- Education$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 26 | $395 |
| Novo Nordisk | 16 | $287 |
| AstraZeneca | 16 | $271 |
| Amgen | 12 | $228 |
| Pfizer | 9 | $162 |
| Dexcom, Inc. | 6 | $151 |
| Boehringer Ingelheim | 7 | $135 |
| AbbVie | 7 | $121 |
| GSK | 6 | $104 |
| Abbott | 5 | $100 |
| Exact Sciences | 5 | $98 |
| Otsuka America Pharmaceutical, Inc. | 4 | $97 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $68 |
| Teva Pharmaceuticals USA, Inc. | 4 | $66 |
| Novartis | 3 | $48 |
| Idorsia Pharmaceuticals US Inc | 3 | $44 |
| Phathom Pharmaceuticals, Inc. | 6 | $43 |
| Bayer | 2 | $36 |
| Merck | 2 | $30 |
| Bioventus LLC | 2 | $29 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Fidia Pharma USA Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $19 |
| Irhythm Technologies, Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Pacira Pharmaceuticals Incorporated | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
How this compares
$2,670 in reported general payments places this provider in the 75th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 86 | $117,099 |
| FarxigaDapagliflozin Propanediol | 69 | $89,831 |
| MounjaroTirzepatide | 59 | $83,998 |
| JardianceEmpagliflozin | 55 | $75,926 |
| EliquisApixaban | 62 | $72,220 |
| Repatha SureclickEvolocumab | 63 | $60,180 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $54,614 |
| ProliaDenosumab | 31 | $52,645 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $39,305 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $30,162 |
| TrulicityDulaglutide | 19 | $29,473 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $17,964 |
| XareltoRivaroxaban | 25 | $17,909 |
| LinzessLinaclotide | 18 | $17,528 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 31 | $9,698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $271 | $119,993106 claims |
| Novo NordiskOzempic | $287 | $117,09986 claims |
| Lilly USA, LLCMounjaro, Trulicity | $395 | $113,47178 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Shingrix | $104 | $76,878149 claims |
| Boehringer IngelheimJardiance | $135 | $75,92655 claims |
| PfizerEliquis | $162 | $72,22062 claims |
| AmgenProlia | $228 | $52,64531 claims |
| AbbVieLinzess, Synthroid | $121 | $21,17270 claims |
| Johnson & JohnsonXarelto | $14 | $17,90925 claims |
| MerckJanuvia | $30 | $8,06413 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $3,514387 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Cleveland
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.